isoform responsible for "housekeeping" functions, such as gastrointestinal cytoprotection, platelet aggregation, parturition, and renal homeostasis, whereas COX-2 is expressed only in response to inflammatory and mitogenic stimuli. Although some COX-2 inhibitors demonstrated anti-inflammatory efficacy and improved gastrointestinal profile compared with traditional NSAIDs or placebo (1), they were associated with a small but consistent increase in the incidence of cerebrovascular and cardiovascular events in several clinical trials, which led to their withdrawal from the market (3, 31) . Molecular mechanisms behind the cardiovascular effects of COX-2 inhibition have been postulated (12) . Several studies strongly support a protective role of PGI 2 in the cardiovascular system (5, 10, 29) . Thus, coxibs inhibit the production of PGI 2 , a potent inhibitor of platelet aggregation and vasodilator, derived from COX-2 while leaving COX-1-derived TXA 2 synthesis in platelets unchanged, creating a prothrombotic hazard (9, 14) . However, COX-2 expression in normal vascular endothelium appears to be limited, and other hypotheses have been argued (12, 20) .
In human kidney, while COX-1 is widely expressed, COX-2 is constitutively found primarily within the macula densa, thick ascending limb, and papillary interstitial cells. Interestingly, COX-2 expression at these sites is modulated by high-and low-salt intake, suggesting a role for COX-2 in blood volume regulation (4, 15, 28, 32) . Indeed, COX inhibitors have been associated with a mild-to-moderate increase in blood pressure and with papillary necrosis and renal failure, when used chronically. Moreover, when the gene encoding mouse COX-2 (Ptgs2) is knocked out or encodes an active site mutation Y385F, the animals display severe renal developmental abnormalities, conditioned by genetic background, that may progress to renal failure during adult life (7, 21, 23, 35, 37) , suggesting that COX-2 plays an important role in kidney homeostasis. To understand the therapeutic usefulness of COX inhibitors and their risk-benefit ratio, it is important to determine the relative contribution of COX-1 and COX-2 to the production of defined prostanoids in specific tissues, such as in the vasculature and kidney. However, currently available NSAIDs, including coxibs, are not entirely selective for one isoform and have heterogeneous pharmacokinetic and pharmacodynamic properties.
To address these issues, we resorted to a targeted COX-2 isozyme knockdown strategy that we had previously used for COX-1 (36) . We developed a novel murine strain (COX-2 Neo/Neo ) genetically manipulated to express low levels of COX-2, in an attempt to mimic the level of maximal pharmacological suppression obtained with COX-2 inhibitors. We aimed to elucidate the role of COX-2 in microvascular thrombogenesis in response to endothelial damage using intravital microscopy and to see whether we could rescue the renal phenotype observed with COX-2 null/mutant mice and titrate the level of kidney COX-2 expression necessary for normal renal homeostasis, function, and maintenance of blood pressure.
MATERIALS AND METHODS

Generation of COX-2
Neo/Neo mice. All procedures were reviewed and approved by the Animal Care Committee of Queen's University. A 7.7 kb NheI/XbaI restriction fragment (containing Ptgs2 exons 1-9) was subcloned as 5Ј arm upstream of a LoxP-flanked neomycin cassette (Neo) into a modified pPNT vector (37) . Then a 3.5 kb 3Ј arm containing Ptgs2 exon 10 and 3Ј flanking sequence (Xba I/XmnI restriction fragment) was cloned downstream of the LoxP-Neo site, using appropriate linkers (Fig.  1A) . The COX-2
Neo targeting vector was linearized with NotI and electroporated into TL-1 embryonic stem (ES) cells. Positive clones (2 of 192) were selected with 250 g/ml G418 and 2 M ganciclovir. Homologous recombination events were screened by Southern blot analysis after Bsu36I or BsrGI digestion using a 3Ј end probe amplified from genomic DNA with the following primers: forward probe, 5Ј-ACAGAACAGACAGAAGCTTGAGC-3Ј and reverse probe, 5Ј-TCAAGGCTATACAGTGAGACC-3Ј. Correct targeting events were further verified by Southern blot with BsrGI digestion of ES cell genomic DNA (Fig. 1B) . Targeted clones were injected into 3.5-day-postcoital C57BL/6J blastocysts, and resulting chimeras were backcrossed to C57BL/6J to determine germ line transmission of the targeted allele. Subsequent genotyping was performed routinely by PCR on DNA isolated from tail biopsies; primer one, 5Ј-TTGACCAGAGCA-GAGAGATG-3Ј; primer two, 5Ј-CATCTGTTCTCCTCAATACTGG-3Ј; and primer 3 in the Neo cassette (5Ј-GAGAATGAAGTGTATGTG-GAAC-3Ј). These primers amplified bands of 360-bp from COX-2 Neo and 566-bp from wild-type (WT) alleles (Fig. 1C) .
Cell culture and Western blot analysis. Thioglycollate-elicited macrophages were harvested immediately after euthanization of mice by CO 2 inhalation using peritoneal lavage and seeded in RPMI 1640 containing 10% FBS. After removal of nonadherent cells, macrophages were treated with LPS (10 g/ml; Sigma-Aldrich, St. Louis, MO) for different time points (2-16 h) or with medium alone. Cell culture medium was collected and stored at Ϫ80°C until assessment of PGE 2 and TXB2. Whole cell lysates were prepared in T-PER lysis buffer (Pierce, Rockford, IL), sonicated on ice (3 ϫ 5 s), and stored at Ϫ80°C until Western blot analysis. Kidneys were dissected from three mice of each genotype, perfused with ice-cold PBS, and immediately snap-frozen and pulverized with a porcelain pestle/mortar in liquid nitrogen. This was followed by homogenization in a Dounce glass tissue grinder (Kontes Glass, Vineland, NJ) on ice in T-PER (5 ml/200 mg tissue), sonication on ice (3 ϫ 5 s) and centrifugation at 10,000 g for 10 min. Proteins from cell homogenates were separated by 10% SDS-PAGE and transferred to PVDF membranes. After overnight blocking, COX-2, COX-1, and ␤-actin were detected with the following primary antibodies incubated in 5% milk-1% Tween 20-TBS solution: rabbit polyclonal anti-COX-2 (cat. #160126; Cayman Chemical, Ann Arbor, MI); rabbit polyclonal anti-COX-1 (cat. #160109; Cayman Chemical); anti-␤-actin clone AC15 (cat. # A5441; Sigma-Aldrich) and appropriate HRP-conjugated secondary antibodies. Immunodetection was visualized with enhanced chemiluminescence-plus detection reagent (GE-Amersham), and digitized images were recorded with a FluorChem 8900 instrument (Alpha Innotech, San Leandro, CA). Protein band intensities were quantitated with ImageJ (available from National Institutes of Health at www.nih.gov).
Endothelial cells were isolated from three COX-2 Neo/Neo and three COX-2 ϩ/ϩ mouse spleens following euthanasia by CO2 inhalation. Briefly, the mononuclear fraction of whole spleen homogenates was separated using Ficoll-Paque Plus (GE Healthcare, New York, NY) and seeded in EGM-2 medium supplemented with 10% FBS (Lonza, Basel, Switzerland). Fresh culture medium was added every other day until the formation of small, round colonies of cobblestone-like morphology was observed (ϳ21 days). At confluency, cells were selected for the expression of endothelial cell marker CD31 (PECAM) using anti-CD31-covered microbeads (Dynabeads, Invitrogen, Carlsbad, CA) as per the manufacturer's instructions. The endothelial phenotype was confirmed by analysis of specific endothelial markers [VEGF, VEGF receptor-1 (VEGFR-1), VEGFR-2, endothelial nitric oxide synthase, von Willebrand factor, and CD31] and formation of capillary-like structures in Matrigel. Endothelial cell homogenates were prepared and analyzed by Western blot analysis, as described above, for peritoneal macrophages. In addition, prostacyclin synthase (PGIS) was analyzed using a rabbit polyclonal anti-PGIS antibody (cat. no. 100023; Cayman).
Quantitative RT-PCR. Macrophages and whole kidneys were lysed in TRIzol (Invitrogen), and total RNA was extracted as per manufacturer's instructions. RNA integrity was verified with an Agilent 2100 Bioanalyzer (Agilent Technology, Santa Clara, CA) and quantitated spectrophotometrically (ND1000; Nanodrop, Thermo Scientific, Wilmington, DE). 1 g of total RNA was reverse-transcribed using SuperScript III firststrand synthesis system (Invitrogen). cDNA (80 ng) was added to 25 l 2ϫ SYBR Green Master Mix (Applied Biosystems, Foster City, CA) plus 5 l each of sense/antisense primers (200 nM final concentration). Primers spanning one intron and amplifying short amplicons were selected to assure specificity and efficiency of amplification reactions (PrimerExpress v.2.0 Software, Applied Biosystems). Primer sequences for genes of interest were as follows: COX-2 forward 5Ј-AGCCAG-GCAGCAAATCCTT-3Ј and reverse 5Ј-ATTCCCCACGGTTTT-GACA-3Ј; COX-1 forward 5Ј-GTTCCGAGCCCAGTTCCAATA-3Ј and reverse 5Ј-AACTGCTCGTAGCTGTACTCTTGTGA-3Ј; 18S rRNA forward 5Ј-TGTCTCAAAGATTAAGCCATGCAT-3Ј and reverse 5Ј-AACCATAACTGATTTAATGAGCCATTC-3Ј; GAPDH forward 5Ј-CTGGAGAAACCTGCCAAGTA-3Ј and reverse 5Ј-TGTT-GCTGTAGCCGTATTCA-3Ј. Real-time PCR was performed with an Applied Biosystems 7500 real-time PCR instrument. Nonreverse transcribed total RNA samples and nontemplate controls were used to verify absence of genomic DNA contamination and nonspecific PCR products. Dissociation curve analysis (melting curve) following each amplification reaction confirmed the generation of primer-specific products. RNA expression was determined using the Ct analysis settings of 7500 System Sequence Detection Software v1.3 based on the ⌬⌬Ct comparative method of relative quantification. 18S rRNA or GAPDH were used as endogenous control genes. Results were expressed as fold-change relative to the control wild-type group. Urine collection and prostanoid measurement. A 24-h urine collection was performed in three 96-well plates placed in parallel in the bottom of the mouse cage of adult mice (mean age: 7-8 mo; gender matched). Urine was briefly centrifuged to remove any particulate matter and stored at Ϫ80°C until prostanoid measurement. Prostanoid urinary metabolites (PGEM, 2,3-dinor-6-keto-PGF 1␣, 2,3-dinor-TXB2, 6-keto-PGF1␣) were analyzed by GC/MS, as described previously (6). PGE2 and TXB2 in cell medium from macrophages and TXB2 from murine serum were analyzed by LC-GC/MS, as described previously (36 (mean age: 5-5.5 mo) with approximately equal numbers of male/ females were dissected, weighed, gently cut along the longitudinal axis, and immediately immersed in 10% buffered formalin. After fixation, kidneys were paraffin-embedded, sectioned, and stained with both hematoxylin and eosin and periodic acid-Schiff for evaluation. A pathologist scored renal histopathology from 0 to 4 (0, normal; 1, minimal focal changes; 2, mild, scattered to multifocal changes; 3, moderate, locally extensive changes; 4, marked changes according to the presence or severity of 1) glomerular hypoplasia, 2) glomerular hyperplasia, 3) tubular regeneration, 4) tubular dilation/degeneration, 5) change in thickness of the renal cortical mantle and 6) leukocyte inflammation, with a maximum score of 24. Scoring was conducted using blinded slides, and findings were peer-reviewed by a second pathologist for concordance. ϩ/ϩ and COX-2 Neo/Neo macrophages after same treatments. 18S rRNA is the housekeeping gene used as endogenous control (n ϭ 3). E: PGE2 and TXB2 synthesis from macrophages of COX-2 ϩ/ϩ and COX-2 Neo/Neo mice, expressed as LPS-induced increase over baseline. The stimulation of COX-2 ϩ/ϩ macrophage-derived prostanoids was significantly greater than for COX-2 Neo/Neo ; *P Ͻ 0.05, n ϭ 4.
Serum was obtained by centrifugation of whole blood, allowed to clot for 30 min at 37°C, and stored at Ϫ80°C until measurements of blood urea nitrogen (BUN) and electrolytes, as routinely performed in the Kingston General Hospital, Kingston, Canada.
Glomerular filtration rate. Glomerular filtration rate (GFR), a direct index of kidney function, was performed by inulin clearance, as previously described (25) . Briefly, fluorescently labeled inulin (FITCinulin, Sigma) was injected into COX-2
Neo/Neo and COX-2 ϩ/ϩ mice (n ϭ 8 for each group, 3-5 mo age) as a single bolus via the tail vein (187 mg/g body wt). At 3, 10, 15, 35, 75, 100, and 120 min postinjection, blood samples were collected in a heparinized glass microcapillary. Plasma was separated by centrifugation at 2,000 rpm for 5 min. Plasma (10 l) was added to 500 mM HEPES (40 l; pHϭ7.4), and fluorescence was detected with a plate reader (485 nm excitation/535 nm excitation; FLUOstar Optima; BMG Labtech, Offenburg, Germany). A standard curve was prepared using known concentrations of FITC-inulin in HEPES buffer to assure that fluorescence measurements were directly proportional to FITC-inulin (linear regression coefficient Ͼ0.98). Two-phase exponential decay nonlinear regression was employed for calculation of GFR (Graph Pad software, GraphPad Prism, San Diego, CA).
Blood pressure measurements. Blood pressure was monitored in adult (6 -9 mo) conscious mice in the ascending aorta via cannulation of the left carotid artery with of a PA-C10 transmitter device (DSI). Implantation of the transmitter was performed under ketamine (90 mg/kg)/xylazine (5 mg/kg) anesthesia, according to the manufacturer's protocols. After complete recovery from surgery (Ϸ7 days), blood pressure was monitored for 1 wk with one recording every 4 min in a continuous manner (360 recordings/day for each mouse) (Dataquest ART system, DSI, St. Paul, MN). The daily average was calculated for mean arterial pressure, systolic pressure, diastolic pressure, and heart rate.
In vivo model of thrombosis. Anesthetized adult male mice (mean age: 6.5-8.5 mo) were placed on a custom-made Plexiglas platform, heated to 37°C. The right external jugular vein was cannulated with a polyethylene (PE)-20 catheter for subsequent intravenous injections. A small incision was performed on the scrotum along the midline and one testicle exposed by applying gentle pressure on the abdomen. The cremaster muscle was gently separated from the testicle, anchored with three 6-0 silk sutures to hold it open and the testicle was pushed back into the body cavity. The exposed cremaster muscle was continuously perfused with PBS. The microvasculature in the cremaster muscle was visualized by microscopy with a NPL Fluotar (Leitz ,Wetzlar, Germany) ϫ25 objective. Rhodamine 6G (1 mg/ml solution; Sigma-Aldrich) was injected intravenously to fluorescently label platelets in vivo. Fluorescence was detected with a filter cube at 575 Ϯ 20 nm. A Whatman filter paper square (0.5 ϫ 0.5 mm) soaked in 10% FeCl 3 solution was applied topically for 3 min to induce endothelial injury and then removed. Digital sequence images were captured (Hamamatsu Orca-ER camera) over a 40-min period or until complete vessel occlusion. Fluorescence intensity (brightness) of platelet aggregates was measured by manually setting the threshold on a grayscale of 0-4095. Area and integrated optical density of bright objects over threshold were measured and corrected by the background brightness for each image (Image ProPlus 5.1; Media Cybernetics, Silver Spring, MD). Data are expressed as arbitrary units (AU).
Ex vivo platelet aggregation. Blood (0.5 ml) was drawn from the inferior vena cava into an Eppendorf tube and allowed to clot for 1 h at 37°C in a water bath. Serum was separated by centrifugation and stored at Ϫ80°C until TXB 2 measurement by GC/MS.
Statistics. Data are expressed as means Ϯ SE; Student's t-test was used for comparisons between COX-2
Neo/Neo and COX-2 ϩ/ϩ groups; P Ͻ 0.05 were considered significant.
RESULTS
Characterization of COX-2
Neo/Neo mice, a novel model of COX-2 knockdown. We generated a novel murine strain (COX-2 Neo/Neo ) by specifically targeting Ptgs2 with insertion of a neomycin-resistance cassette into the final intron of the gene (Fig. 1) . This strategy has been reported to yield a hypomorphic allele or knockdown of gene expression (34, 36) . As the level of knockdown cannot be predicted a priori, we selected two cell types for detailed studies: peritoneal macrophages and vascular endothelial cells. Unstimulated COX-2
Neo/Neo macrophages expressed almost 80% less COX-2 protein than COX-2 ϩ/ϩ cells (Fig. 2, A and B) by Western blot analysis. COX-2 ϩ/ϩ macrophages showed 12-fold induction of COX-2 protein in response to LPS, and this induction was drastically blunted in COX-2
Neo/Neo macrophages. COX-1 expression was similar between COX-2 Neo/Neo and COX-2 ϩ/ϩ macrophages and remained constant after LPS challenge in both groups (Fig. 2A) . Furthermore, COX-2 Neo/Neo macrophages failed to significantly induce COX-2 expression in response to LPS at several time points between 2 and 16 h, in contrast to the striking induction in COX-2 ϩ/ϩ cells (Fig. 2C) . Similar results were obtained for COX-2 mRNA by real-time quantitative PCR analysis before and after LPS treatment (Fig. 2D) , while COX-1 mRNA expression was unchanged (data not shown). In terms of prostaglandin synthesis, LPS-induced PGE 2 and TXB 2 levels increased only two-fold or less in COX-2 Neo/Neo macrophages, compared with 87-and 5-fold, respectively, in COX-2 ϩ/ϩ macrophages (Fig. 2E) . Similar to peritoneal macrophages, in endothelial cells isolated from COX-2 Neo/Neo mice, COX-2 expression was markedly suppressed compared with COX-2 ϩ/ϩ cells ( Fig. 3 and quantitation in graph). COX-2 ϩ/ϩ endothelial cells treated for 6 h with IL-1␤ as an inflammatory stimulus, induced COX-2 protein 2.5-fold over unstimulated endothelial cells. There was some induction in COX-2 Neo/Neo endothelial cells, but levels of COX-2 were significantly blunted compared with the control cells. COX-1 and PGIS, the isomerase responsible for the specific conversion of COX-derived PGH 2 into PGI 2 , were not significantly different in COX-2 Neo/Neo compared with COX-2 ϩ/ϩ endothelial cells. Unstimulated COX-2 Neo/Neo endothelial cells produced 11 Ϯ 0.3 ng/ml PGI 2 (measured as stable hydrolysis product 6-oxo-PGF 1␣ ) in the cell-conditioned medium. This represents ϳ70% reduction compared with basal PGI 2 production in COX-2 ϩ/ϩ endothelial cells (34 Ϯ 1.6 ng/ml). Since COX-1 and PGIS protein were not affected by Ptgs2 gene manipulation, our data suggest that COX-2 expression is a major determinant of PGI 2 production in these spleen-derived endothelial cells.
COX-2 knockdown reduces total body prostacyclin, but not PGE 2 or thromboxane, biosynthesis. 2,3-dinor-6-keto-PGF 1␣ , the major urinary metabolite of prostacyclin metabolism (2, 27) was significantly reduced by Ϸ50% in COX-2 Neo/Neo compared with COX-2 ϩ/ϩ mice (1.2 Ϯ 0.1, n ϭ 21 vs. 2.6 Ϯ 0.7, n ϭ 18 ng/mg creatinine; P Ͻ 0.05) (Fig. 4) . However, in vivo synthesis of other COX-derived prostanoids, PGE 2 and TXA 2 , measured as their major urinary metabolites 11␣-hydroxy-9,15-dioxo-tetranor-prostane-1,20-dioc acid (PGEM) and 2,3-dinor-TXB 2 , respectively, were not significantly different in COX-2
Neo/Neo compared with COX-2 ϩ/ϩ mice (PGEM: 3.1 Ϯ 0.4 ng/mg creatinine, n ϭ 19 vs. 3.1 Ϯ 0.8, n ϭ 17 and 2,3-dinor-TXB 2 : 47 Ϯ 15 ng/mg creatinine, n ϭ 21 vs. 48 Ϯ 16, n ϭ 20; P ϭ not significant) (Fig. 4) . These data suggest that under physiological conditions, COX-2 is an abundant source of prostacyclin, whereas PGE 2 and TXA 2 derive mainly from COX-1 activity, in accordance with previous reports in mice and humans (6, 18) .
COX-2 knockdown results in a modest renal phenotype intermediate between COX-2 mutant Y385F and COX-2 wildtype mice.
COX-2 null mice or mice with an active site COX-2 mutation (COX-2 Y385F/Y385F ) display severe postnatal renal developmental abnormalities dependent on genetic background (7, 21, 23, 35, 37) . Additionally, the use of NSAIDs, including coxibs, has been associated with nephropathies and renal hypertension. COX-2 Neo/Neo mouse adult kidneys demonstrated subtle but consistent differences compared with controls but much less severe compared with COX-2 Y385F/Y385F mice (histopathological scores: 11.25 vs. 4 vs. 16.5). Specifically, changes in COX-2 Neo/Neo mice consisted of moderate, multifocal hypoplasia of glomerular tufts within the superficial renal cortex, mild, multifocal glomerular hyperplasia within the deeper cortex, and mild-moderate, multifocal tubular degeneration and regeneration, particularly within the superficial cortex compared with control mice (Fig. 5) . There was no evidence of perivascular or interstitial inflammation with indistinguishable patterns between the sexes. COX-2 Y385F/Y385F kidneys, on the other hand, are characterized by an almost complete loss of the cortical mantle (Fig. 5, A and B ϩ , Cl Ϫ , data not shown) and glomerular filtration rates (0.67 Ϯ 0.14 COX-2 ϩ/ϩ , n ϭ 8 vs. 0.60 Ϯ 0.12 ml/min COX-2 Neo/Neo , n ϭ 8) (Fig. 6A) . Urinary excretion of 6-keto-PGF 1␣ , an index of prostacyclin produced locally in the kidney, known to play a major role in renal blood flow regulation, was not significantly different in COX-2 Neo/Neo vs. COX-2 ϩ/ϩ mice (2.1 Ϯ 0.3 ng/mg creatinine, n ϭ 11 vs. 1.5 Ϯ 0.3, n ϭ 8). Real-time quantitative PCR analysis of whole kidney total RNA (Fig. 6B) and protein (Fig. 6C) , confirmed that COX-2 mRNA and protein were suppressed in COX-2 Neo/Neo mice compared with COX-2 ϩ/ϩ mice, while COX-1 mRNA and protein levels were relatively unchanged (Fig. 6, B and C) .
As renal pathology can markedly affect blood pressure and because long-term coxib administration is associated with mild to moderate risk for hypertension in controlled trials (9, 28), we measured blood pressure telemetrically in COX-2 Neo/Neo and control mice. No evidence for alteration in mean, systolic, and diastolic arterial blood pressures between groups of mice were observed (111 Ϯ 0.7, 122 Ϯ 0.8, 99 Ϯ 0.7, COX-2 Neo/Neo , n ϭ 6 vs. 111 Ϯ 1.1, 122 Ϯ 1, 100 Ϯ 1.2 mmHg, COX-2 ϩ/ϩ , n ϭ 7; see Fig. 7 ). Similarly, heart rate values were not significantly different between the two groups (575 Ϯ 22 bpm, COX-2 Neo/Neo vs. 563 Ϯ 26 bpm, COX-2 ϩ/ϩ ) (Fig. 7B) . There was no evidence for changes in these parameters with respect to circadian activity (not shown).
Increased propensity for thrombogenesis in COX-2
Neo/Neo mice visualized by intravital microscopy in a model of arterial thrombosis. We investigated the thrombotic response in the setting of profound COX-2 inhibition as occurs in endothelial cells of COX-2 Neo/Neo mice. We employed a previously described model of arterial thrombosis (8) induced by FeCl 3 and visualized by fluorescently labeled platelets in cremaster muscle arterioles using intravital microscopy (mean arteriole diameter: 48.9 Ϯ 3.6 m and 49.2 Ϯ 3.9 m for COX-2 Neo/Neo , n ϭ 13 and COX-2 ϩ/ϩ , n ϭ 14, respectively). COX-2 Neo/Neo mice showed an increased propensity for thrombogenesis in response to FeCl 3 -induced injury compared with COX-2 ϩ/ϩ littermates (Fig. 8, A and B) . The overall formation of platelet aggregates adhering to the injured vessel was significantly higher in COX-2 Neo/Neo than COX-2 ϩ/ϩ mice (37.9 Ϯ 8.9 in COX-2 Neo/Neo vs. 15.5 Ϯ 4.3 units in COX-2 ϩ/ϩ ; Fig. 8C ). However, over the 40-min observation period, we did not observe a significant difference in occlusive events in COX-2 ϩ/ϩ and COX-2 Neo/Neo mice, and complete vessel occlusion occurred infrequently in both groups under the experimental conditions employed here (only 3 in 13 COX-2 Neo/Neo and 2 in 14 COX-2 ϩ/ϩ mice). We investigated whether an increased platelet activity might have contributed to the enhanced thrombotic response observed in COX-2 Neo/Neo mice. Platelet activation was studied ex vivo by measuring serum TXB 2 formation during whole blood coagulation. COX-2 Neo/Neo mice produced 329 Ϯ 39 ng/ml TXB 2 (n ϭ 4) under the experimental conditions employed, whereas COX-2 ϩ/ϩ animals produced similar TXB 2 levels (279 Ϯ 53 ng/ml, n ϭ 4; P ϭ not significant). Because Neo/Neo mice display minimally perturbed kidney function. A: indices of renal function (BUN, blood urea nitrogen, n ϭ 10 -13 and GFR, glomerular filtration rate, n ϭ 8) measured for both COX-2 ϩ/ϩ and COX2Neo/Neo mice. *P Ͻ 0.05. B: COX-2 and COX-1 mRNA expression in whole kidney. Data are normalized by GAPDH and expressed as fold-change relative to wild type. GAPDH, glyceraldehyde 3-phosphate dehydrogenase. n ϭ 5; *P Ͻ 0.05. C: COX-2, COX-1 and ␤-actin protein expression in whole kidney homogenates from three COX-2 ϩ/ϩ and three COX-2 Neo/Neo mice. Each lane represents the kidney from a single mouse. platelets are considered the major source of TXA 2 in vivo, these data confirm that COX-2 genetic manipulation did not affect COX-1 expression and activity in COX-2
Neo/Neo mice, in accordance with results using macrophages, endothelial cells, and measurement of thromboxane metabolite urinary excretion (vide supra).
DISCUSSION
The biological effects of COX-derived prostanoids are pleiotropic and tissue-specific (11, 30) . COX inhibitors (NSAIDs), a chemically heterogeneous class of drugs with a spectrum of selectivity toward COX-1 and COX-2, differentially modulate the array of prostanoid biological functions. However, it is not always straightforward to evaluate the selective activities directed to each isoform and their associated beneficial and detrimental effects due to a variety of pharmacokinetic and pharmacodynamic variables. Moreover, selective COX-2 inhibitors (coxibs), despite their anti-inflammatory properties and gastrointestinal tolerability, came under scrutiny because of increased risk for cardiovascular and cerebrovascular events compared with nonselective NSAIDs or placebo (1, 3, 9, 12, 14, 31) . To circumvent some of the pharmacological variables, we sought to create a novel animal model that resembles the administration of a selective COX-2 inhibitor, by engineering mice with a hypomorphic allele for Ptgs2 (COX-2 Neo/Neo ) that results in a profound and specific knockdown of COX-2 expression and activity. Macrophages isolated from COX-2 Neo/Neo express less than 30% residual COX-2 protein and mRNA compared with wild-type controls and LPS-induced PGE 2 production, reflecting the inflammatory potential of this cell type, is nearly completely abrogated. Similarly, in COX-2 Neo/Neo endothelial cells COX-2 expression and PGI 2 production are compromised significantly. In addition, COX-1 expression and activity are not compensatorily regulated in COX-2
Neo/Neo mice, as demonstrated in macrophages, endothelial cells, and by measurement of thromboxane metabolite urinary excretion. Therefore, judging from the current experimental data, success has been achieved by this genetic strategy to develop a novel murine strain, in which COX-2 expression and activity are dramatically reduced, but not completely abolished in response to an inflammatory stimulus such as LPS or IL-1␤, thus partly mimicking the effects of a selective COX-2 inhibitor.
Chronic administration of NSAIDs has been associated with nephropathies, varying from marginally increased GFR and sodium retention with mild-to-moderate hypertension to papillary necrosis and renal failure (28, 32) . COX-2 null and COX-2 Y385F/Y385F mutant mice are characterized by a severe renal phenotype due to perinatal renal dysplasia and associated development of kidney architecture (7, 21, 37) . In COX-2 Neo/Neo mice, glomerular and tubular structures were mildly compromised, but kidneys were otherwise normal with no sign of chronic inflammation. COX-2 Neo/Neo mice displayed slightly elevated blood urea nitrogen levels [40 mg/dl compared with reference levels of 20 -30 mg/dl for mice of C57BL/6 or 129 Sv genetic backgrounds observed here and elsewhere (35) ], but other indices of renal function, such as GFR measured by FITC-inulin clearance, or electrolytes were not significantly different from control mice. The levels of BUN in COX-2 Neo/Neo mice were substantially lower than those previously reported for COX-2 null and COX-2 Y385F/Y385F mice on mixed C57BL/ 6 ϫ 129Sv or backcrossed mice of these genetic backgrounds, with nearly identical values for the COX-2 ϩ/ϩ mice in these studies ( Fig. 6 ; Refs. 23, 35, 37) and no alterations in blood pressure in COX-2 Neo/Neo mice. In addition, the renal production of PGI 2 , synthesized mainly by COX-1, an important regulator of renal blood flow, measured as its urinary metabolite 6-keto-PGF 1␣ , was not affected in COX-2 Neo/Neo mice. Taken together, our results show that despite modest morphological changes, kidney function is not greatly affected in settings of dramatic reduction (Ϸ90%) of COX-2 expression, Fig. 7 . COX-2 knockdown does not affect blood pressure and heart rate monitored telemetrically in conscious mice. Daily averages of blood pressures and heart rates recorded every 4 min (360 recordings/day for each mouse) from 6 COX-2
Neo/Neo and 7 COX-2 ϩ/ϩ mice. A: mean arterial pressure. B: heart rate. bpm, beats per minute. C: diastolic pressure. D: systolic pressure.
suggesting that these mice will be useful for assessment of COX-2 functions in adult mice without significant confounding renal problems. Previously, we showed that COX-1 could partially rescue the complete loss of COX-2 protein in the kidney in another unique strain of mice in which COX-1 replaces COX-2 (38). Our current findings suggest that COX-2 is essential for normal kidney development but that COX-1-and/or residual COX-2-derived prostaglandin synthesis is sufficient to sustain normal kidney function in adult mice when COX-2 expression is drastically reduced. However, it remains to be determined if the renal phenotype will be modified on different genetic backgrounds other than studied here, as genetic strain differences have been noted (35) . Since coxib administration has been associated with an increase in the incidence of myocardial infarction, most likely from enhanced atherothrombotic events, in several clinical trials (3, 14, 31) , in the present study, we investigated the propensity toward arterial thrombosis in vivo using our novel genetic model of COX-2 knockdown combined with intravital microscopy imaging. The thrombotic response to endothelial oxidative damage by ferric chloride was significantly greater in COX-2 Neo/Neo mice compared with wild-type controls in our experimental settings. Our results strongly support the hypothesis that COX-2-dependent mechanisms are protective in thrombosis and that a reduction of COX-2 activity may pose a prothrombotic hazard in certain settings. These data are consistent with other findings in a canine model of electrolytic vessel wall injury (16, 17) .
COX-2 Neo/Neo and wild-type mice produced similar levels of thromboxane during whole blood coagulation assessed ex vivo. Since COX-1 is the only COX isoform present in mature circulating platelets, and TXA 2 is the major COX-1-derived prostanoid produced in platelets during platelet aggregation, our data suggest that profound knockdown of COX-2 expres- Fig. 8 . COX-2 knockdown mice are more susceptible to FeCl3-induced thrombogenesis. A: intravital microscopy images of cremaster muscle arterioles of COX-2 ϩ/ϩ (left) and COX-2 Neo/Neo (right) mice. Digital images were captured after endothelial injury at the indicated time points (in minutes). Bright field (BF) and rhodamine (Rhod.) fluorescence were recorded before injury. Images are representative of 14 and 13 mice for COX-2 ϩ/ϩ and COX-2 Neo/Neo groups, respectively. B: fluorescence intensity, representing rhodamine-labeled platelets adhering to the arteriole after the thrombogenic stimulus over 40-min period, expressed as arbitrary units (AU). C: overall thrombogenic activity for COX-2 ϩ/ϩ and COX-2 Neo/Neo arterioles in response to FeCl3 was calculated from area under the curve (AUC) analysis of data from B.
sion in COX-2
Neo/Neo mice does not affect platelet activation nor platelet COX-1 capacity for producing TXA 2 in response to thrombin. However, we cannot exclude that COX-2-dependent, platelet-independent mechanisms, probably involving components of the coagulation cascade, may contribute to the increased thrombotic response observed in COX-2 Neo/Neo mice. Indeed, it has recently been proposed that COX-2 inhibitors abolish endothelial COX-2-derived endocannabinoid-dependent suppression of tissue factor, an initiator of blood coagulation, via activation of PPAR␦ receptors (13) , leading to a potential prothrombotic scenario. In another study, COX-2-and PGI 2 -dependent expression of thrombomodulin, an important regulator of thrombosis, has been demonstrated in vascular smooth muscle cells, suggesting that coxibs may decrease this endogenous restraint on thrombin generation (26) . Whether tissue factor, thrombomodulin, and/or other molecules involved in blood coagulation modulate platelet aggregation in our experimental system needs further investigation. PGI 2 production is profoundly reduced following administration of COX-2 inhibitors in healthy subjects and mice (4 -6, 18, 19) . In COX-2
Neo/Neo mice, in vivo PGI 2 production was reduced by about 50% compared with wild-type mice (Fig. 4) . Since PGI 2 is a potent antiaggregatory and vasodilatory compound produced in blood vessels, a marked reduction in prostacyclin synthesis as in COX-2
Neo/Neo mice, may explain, in part, the increased thrombotic response observed. Indeed, Murata et al. (22) showed that mice lacking the prostacyclin receptor (IP) have an increased thrombotic response in a model of thrombosis similar to the one used here.
In conclusion, we generated a novel murine model of profound and specific COX-2 inhibition that should be suitable to study COX-2-dependent processes in long-term studies. Our findings identify extra-renal COX-2 as a major source of PGI 2 in vivo that plays an important protective role in the regulation of thrombosis. The increased thrombotic activity in mice with COX-2 knockdown in these experimental settings supports the hypothesis that individuals taking coxibs, resulting in low COX-2 activity, could be predisposed to increased thrombotic tendency.
